in me since like take the a of business third what join AxoGen, AxoGen, since and compelled plans for going providing us the I thanks, to more get first forward. begin and what few business call I'll quarter leader.
What the this joining brief our to a by I'd been call common my of the operator, of doing August, are AxoGen's have for I new as as overview to joining our CEO is time today. Thanks, everyone, questions address performance. Then our
additional after also our followed will our will I and performance, financial on color provide provide quarterly question this, a Nir Following answer. by some a review results, of which
So let's begin.
last reflecting pleased are to growth. was and growth EBITDA year, an our was portfolio. while increase year. Revenue our quarter strategy. were broad-based, revenue XX% million, and impacted of $XX.X line growth execution top approximately Notably, EBITDA Both the productivity and performance in revenue revenue improved of by present We last was $X.X the versus $X.X positively sales EBITDA quarter's with commercial compared across adjusted million million
since I Regarding X relative with enough the people Everything and business business; AxoGen the of business fulfills in build distinctively the a this am my a the all why standards simply, of AxoGen. is numerous and estimation. most the relevant; observed to credible and advantaged finally, problem clinical common purpose to justify is solution business experienced questions existing clear organization the secondly, elements allocation of required the I've is joining opportunity, evidence to the time, is compelling to for begin care. the capital and success important asked, estimation: of there the firstly, and most as reaffirms purpose I'll Very
AxoGen the many to an still privilege to cardiovascular, over understand good overcome which doing can't that I and love numerous I why and test believe execution market leading therapies very is what potential. is and is plan last important years do, of undeveloped companies, functions, solutions.
I've and occasions apply had the products public learned in business our on I thesis are I with I obviously these function. business electrophysiology purpose years or a While significant mechanics confidence the upon undifferentiated XX-plus by however, have private in to diabetes this I'm ago, bringing future neuromodulation, both dependent our markets. numerous future how it, product across irrelevant transformative and in and mechanics
what and company for mission remaining meet the doing strategies and the guidance of and the our the established for As the our of underlying since business, I X the for to purpose external have year; purpose, successfully two, with develop X, forward? one, revenue plan by our the strategic application; X for status required company's is joining the questions, care processes what been business established relative day of number aim the what to On for achieve a BLA planning market the opportunity. priorities year: business new and is employees submission remainder for number of lastly, the understanding we the going are our products the in stakeholders key engaging standard operating the plan all strategic process.
Consistent objectives, and necessary complete
respective I applications many business the for in on the opportunities, we on on constitute While development which question, their lines critical to in Avance, based call different detail numerous early what plan time in choices. the impact time we was are business opportunities describe development.
Returning market most will we business results. of and of therefore, are we our primary models fourth different the will To forward have business answer, time call different for instances, on return and our therefore, and the opportunities prioritize for one quarterly believe Avance the be required requiring, attractive upon to standard our look strategic details quarter ability the at XXXX, last product, providing models.
How market characterized care founded, by to and and different physician which distinctly points these
a our achieving we release, milestones. As major described solid several in quarter, earnings had overall,
trends FDA and with the the the pleased for importantly, positive BLA and Graft. Avance the line process of performance of completion We by revenue the growth, are in rolling filing the of acceptance Nerve submission bottom the
and/or repair trauma high grow on these expansion with in in business, indications repair including and a characterized the number primarily criteria: the specialties surgical We potential account, nerve procedures; academic already accounts, adoption accounts. by to on size and improvements hospitals, procedure nerve the remains account aim based our to are these in accounts the and head our volume these focus our expanding strategy neck particular. presence and and to in believe following recent building the reason productivity centers algorithm is other lastly, on deepening hospitals in potential Our drive the inherent by which larger of focused for our nerve repair nerve our affiliated in trained microsurgeons.
We trauma of high extremities sales in X growth of within repair on existing accounts through potential high experience types of of targeted Level
nerve saw revenue as as well as procedures. growth reconstruction we in Regarding protection clinical mix, applications an such increase cases including across portfolio, extremity nerve the in our breast upper from trauma, mandible targeted broad-based reconstruction neurotization growth and
is leadership protection during by AxoGen commitment nerve to our newest in soft non-transected solutions, Protector growth continued our address Matrix, Nerve the comprehensive Our these professional which events driven the to of common portfolio gives AxoGuard, in education. quarter HA, Avive+ most nerve adoption programs and include key tissue and injuries.
Other
of year, common protection surgeon Nerve an we repair.
The nerve we Graft national for of This Society in topic collaboration presented our of meeting, the RSensation damage site this novel and damage education in with involved to broader data numerous and incorporating the extent on key also trauma the the of portfolio.
In coaptation Surgery was common motor nerve was imaging American data nerve These leading of in occurs attended that growing the of sensory, from and we important Hand see hand role the at interest continue modalities. repair community. the among QX, a the in Minneapolis. of Avance growing damage and surgeon other injuries, extent a breast surgeon the a program of advanced repair in extent the as new driver of importance quarter, mixed a hand traumas as nerve using of injuries quantifying programs neck. we During nerve and common nerve adoption regional and surgeons. and characterized MicroCT presented programs group are from head activation sponsored This Nerve in extremities well and generated
to how compared lead a zone Importantly, of previously as to visual understanding traumatic than common these extensive appreciated findings of estimation. of methods injury will traditional help lacerations further surgeon's these more a the
rates We recovery direct the important higher performed direct to repair. also role The These study comparing proportion injury saw a of repair. to recovery presentation nerve repair. connector-assisted repair levels in connector-assisted nerve meta-analysis compared understanding of of data meaningful and suture-only a our the publications suture-only of products data and patients meaningful growing recently and from play significantly highlight reported recovery of meaningful when published was greater achieving repair findings
that by determined application completed time we September, XXXX. we Turning BLA process. they X, a to of our for Graft. November informed review submission a and allows review goal In which our September filing sufficiently for FDA date line On permit have were have and approval X, a Nerve Avance substantive to completed review, complete rolling the with the is the
Additionally, not to advisory they informed us hold meeting. planning an that are they currently committee
a BLA to product. As reminder, Graft complete XXX a a approval process biological transition will Avance Nerve regulatory to the
and execution will conclusion, results, market the with to science-based commitments at providing third current development. be XX quarter education designated we market reference from date.
In growth least pleased Importantly, believe Avance our the are of a reflect of strategy we biosimilars, approval for as potential successful years exclusivity and our product which
the Looking for provide on new hand will ahead, plan.
I and over and BLA remain we Nir? our process, year to will our completing revenue details meeting financials focused the guidance strategic operating the year completing full Nir, guidance. application our now further who on call
